Palivizumab - Latest Advances

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Published: December 02, 2025

Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort.

Journal: Expert review of vaccines

Published: November 18, 2025

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: November 14, 2025

Updated Swedish guidelines for the management and treatment of RSV infection.

Journal: Infectious diseases (London, England)

Published: November 08, 2025

Preventing Respiratory Syncytial Virus in Infants: A Comparative Review of Nirsevimab and Maternal Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination.

Journal: Cureus

Published: October 13, 2025

Respiratory syncytial virus. What's new in prevention?

Journal: Seminars in fetal & neonatal medicine

Published: October 08, 2025

Subgroup limitations and imaging variability in palivizumab studies: implications for public health assessment.

Journal: European journal of pediatrics

Published: September 29, 2025

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering.

Journal: mAbs

Published: September 25, 2025

Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom.

Journal: International journal of technology assessment in health care

Published: September 22, 2025

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives.

Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

Published: September 12, 2025

Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea.

Journal: Human vaccines & immunotherapeutics

Published: August 28, 2025

Monoclonal antibodies for preventing respiratory syncytial virus infection in children: a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: August 20, 2025

Filters

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants.

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants.

Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort.

Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Updated Swedish guidelines for the management and treatment of RSV infection.

Updated Swedish guidelines for the management and treatment of RSV infection.

Preventing Respiratory Syncytial Virus in Infants: A Comparative Review of Nirsevimab and Maternal Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination.

Preventing Respiratory Syncytial Virus in Infants: A Comparative Review of Nirsevimab and Maternal Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination.

Respiratory syncytial virus. What's new in prevention?

Respiratory syncytial virus. What's new in prevention?

Subgroup limitations and imaging variability in palivizumab studies: implications for public health assessment.

Subgroup limitations and imaging variability in palivizumab studies: implications for public health assessment.

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering.

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering.

Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom.

Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom.

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives.

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives.

Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea.

Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea.

Monoclonal antibodies for preventing respiratory syncytial virus infection in children: a network meta-analysis.

Monoclonal antibodies for preventing respiratory syncytial virus infection in children: a network meta-analysis.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.